摘要
癌症免疫治疗具有巨大潜力,有望成为癌症治疗的主流手段。在目前的癌症免疫治疗应用中,免疫检查点抑制剂(Immune checkpoint inhibitors,ICIs)已取得显著成效。目前临床上广泛应用的ICIs包括靶向细胞毒性T淋巴细胞相关抗原4(Cytotoxic T lymphocyte-associated antigen-4,CTLA-4)、程序性死亡受体1(Programmed death-1,PD-1)及程序性死亡受体配体1(Programmed death-ligand 1,PD-L1)的抑制剂。此外,溶瘤病毒和嵌合抗原受体T细胞等新型免疫治疗也逐渐进入临床,ICIs相关的联合治疗更是显示出了独特的优势。本文将重点对ICIs、溶瘤病毒、嵌合抗原受体T细胞疗法的单独或组合形式在实体瘤中的应用现状进行综述。
Cancer immunotherapy has great potential and is expected to become the mainstream method of cancer treatment.In the current application of cancer immunotherapy,immune checkpoint inhibitors(ICIs)have achieved remarkable results.The currently widely used ICIs in clinical practice include inhibitors targeting cytotoxic T lymphocyte-associated antigen-4(CTLA-4),programmed death-1(PD-1)and programmed death-ligand 1(PD-L1).In addition,new immunotherapies such as oncolytic viruses and chimeric antigen receptor T cells are gradually entering the clinical practice,and combination therapy related to ICIs has shown unique advantages.This article will focus on the current application status of ICIs,oncolytic viruses,and chimeric antigen receptor T cell therapies in solid tumors either their individual or combined forms.
作者
赵璐(综述)
张正凤(综述)
王大臻(综述)
杨柳(综述)
刘泽(综述)
娄长杰(审校)
ZHAO Lu;ZHANG Zhengfeng;WANG Dazhen;YANG Liu;LIU Ze;LOU Changjie(Department of Gastroenterology,Harbin Medical University Cancer Hospital,Harbin 150081,China)
出处
《实用肿瘤学杂志》
CAS
2024年第1期55-61,共7页
Practical Oncology Journal
基金
北京医学基金(编号:YXJL-2022-0080-0015)。
